Alpha-2,3-sialyltransferase enhances Neisseria gonorrhoeae survival during experimental murine genital tract infection
about
Vaccines for gonorrhea: can we rise to the challenge?Experimental Gonococcal Infection in Male Volunteers: Cumulative Experience with Neisseria gonorrhoeae Strains FA1090 and MS11mkCPhase-Variable Heptose I Glycan Extensions Modulate Efficacy of 2C7 Vaccine Antibody Directed against Neisseria gonorrhoeae Lipooligosaccharide.A bacterial siren song: intimate interactions between Neisseria and neutrophils.Resistance of Neisseria gonorrhoeae to neutrophils.Phosphoethanolamine decoration of Neisseria gonorrhoeae lipid A plays a dual immunostimulatory and protective role during experimental genital tract infection.Opacity proteins increase Neisseria gonorrhoeae fitness in the female genital tract due to a factor under ovarian control.Genomic and metabolic profiling of nonulosonic acids in Vibrionaceae reveal biochemical phenotypes of allelic divergence in Vibrio vulnificusMeningococcal disease and the complement system.Chlamydial infection increases gonococcal colonization in a novel murine coinfection model.α-2,3-sialyltransferase expression level impacts the kinetics of lipooligosaccharide sialylation, complement resistance, and the ability of Neisseria gonorrhoeae to colonize the murine genital tractThe Pathobiology of Neisseria gonorrhoeae Lower Female Genital Tract Infection.Estradiol-Treated Female Mice as Surrogate Hosts for Neisseria gonorrhoeae Genital Tract Infections.Protective role of Toll-like receptor 4 in experimental gonococcal infection of female miceLactate acquisition promotes successful colonization of the murine genital tract by Neisseria gonorrhoeae.Sialylation of lipooligosaccharides is dispensable for the virulence of Haemophilus ducreyi in humansNeisseria gonorrhoeae catalase is not required for experimental genital tract infection despite the induction of a localized neutrophil response.Utilizing CMP-Sialic Acid Analogs to Unravel Neisseria gonorrhoeae Lipooligosaccharide-Mediated Complement Resistance and Design Novel Therapeutics.Impact of fluoroquinolone resistance mutations on gonococcal fitness and in vivo selection for compensatory mutations.A Novel Factor H-Fc Chimeric Immunotherapeutic Molecule against Neisseria gonorrhoeae.Effect of host lactate on gonococci and meningococci: new concepts on the role of metabolites in pathogenicity.Clinically relevant mutations that cause derepression of the Neisseria gonorrhoeae MtrC-MtrD-MtrE Efflux pump system confer different levels of antimicrobial resistance and in vivo fitness.A strain-specific catalase mutation and mutation of the metal-binding transporter gene mntC attenuate Neisseria gonorrhoeae in vivo but not by increasing susceptibility to oxidative killing by phagocytes.Utilizing complement evasion strategies to design complement-based antibacterial immunotherapeutics: Lessons from the pathogenic Neisseriae.Control of pili and sialyltransferase expression in Neisseria gonorrhoeae is mediated by the transcriptional regulator CrgA.Gonococcal lipooligosaccharide sialylation: virulence factor and target for novel immunotherapeutics.In Vivo-Selected Compensatory Mutations Restore the Fitness Cost of Mosaic penA Alleles That Confer Ceftriaxone Resistance in Neisseria gonorrhoeae.
P2860
Q21131153-6E4F0111-FD10-405D-B954-817703A0F23BQ28743428-FFBF773B-EC4F-418F-BBE3-B8810CB99389Q30352495-BA94AF8D-EB24-4661-B33B-FF6F02E561E5Q30422438-5ECB20AB-CEE1-4641-990A-1D81A3CC0B98Q30431442-3FD8BD15-3C0A-4BF2-BC2B-CB6B5F52E846Q33603087-1065D43B-89D8-448F-BD5F-2787F3CEF1AEQ33769104-21555CB4-BAA8-4D8C-8B6F-1B3E0DC00CAAQ33949399-A149554B-BDD2-4EAF-866A-955A224D90F6Q34376170-1C6B6D3D-46F9-49AF-9D79-83339566641AQ34740040-33D2FB78-A7A1-4C8F-B2EA-EC1E1F3BEEFDQ35072338-BD304246-BD14-4207-A145-6DA69DAA9354Q35084650-5684B8D7-8DE5-4E0F-B65B-C7DB6D1B227BQ35086017-1E630C23-5DB5-43E2-95C6-21D4BECB62FBQ35619004-D8256B31-25C9-41ED-8E08-9B94C1FA2CA4Q35689380-A3652C11-E8B5-4158-ABB9-48FA789A3FA4Q35689455-5041F837-5DFB-4AF7-84D0-FF4A1413892CQ35783994-2DBFAFD8-2554-44E6-AD2A-519D1EE81F2CQ35859218-15F8B077-6D1F-47C7-BC2E-5D913BC2E7FFQ36154055-13104644-1722-4D15-A8BC-F94B1EA1A93BQ36553903-B3F6AA34-2AD8-495B-AC5F-1235FB209F9EQ36847072-B334D79E-B59D-461D-B055-0AAE2760DEA4Q37015168-38C63977-2CB4-4BF6-93E3-9DF697E1417EQ37099490-C083BE40-A23F-4219-84FC-0EA13C6660F9Q38864097-FF6B4BD2-24EE-44B8-B8AC-7D5509CAEF5DQ39033896-AAC71177-0F91-486D-9C11-9653CF5BEF34Q40231165-8958DF32-3217-4338-AD2C-94C22B5A0129Q52609076-42E4AF68-2363-4362-98D2-0E8F56B7F54B
P2860
Alpha-2,3-sialyltransferase enhances Neisseria gonorrhoeae survival during experimental murine genital tract infection
description
2006 nî lūn-bûn
@nan
2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Alpha-2,3-sialyltransferase en ...... murine genital tract infection
@ast
Alpha-2,3-sialyltransferase en ...... murine genital tract infection
@en
Alpha-2,3-sialyltransferase en ...... murine genital tract infection
@nl
type
label
Alpha-2,3-sialyltransferase en ...... murine genital tract infection
@ast
Alpha-2,3-sialyltransferase en ...... murine genital tract infection
@en
Alpha-2,3-sialyltransferase en ...... murine genital tract infection
@nl
prefLabel
Alpha-2,3-sialyltransferase en ...... murine genital tract infection
@ast
Alpha-2,3-sialyltransferase en ...... murine genital tract infection
@en
Alpha-2,3-sialyltransferase en ...... murine genital tract infection
@nl
P2860
P356
P1476
Alpha-2,3-sialyltransferase en ...... murine genital tract infection
@en
P2093
P2860
P304
P356
10.1128/IAI.00433-06
P407
P577
2006-07-01T00:00:00Z